Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer

por Ichihara, Seiya, Kunishige, Michihiro, Kadota, Naoki, Okano, Yoshio, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Shinohara, Tsutomu, Takeuchi, Eiji
Publicado 2022

Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib

por Kunishige, Michihiro, Ichihara, Seiya, Kadota, Naoki, Okano, Yoshio, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Shinohara, Tsutomu, Takeuchi, Eiji
Publicado 2022

Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

por Takeuchi, Eiji, Kondo, Kensuke, Okano, Yoshio, Ichihara, Seiya, Kunishige, Michihiro, Kadota, Naoki, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Ogino, Hirokazu, Nokihara, Hiroshi, Shinohara, Tsutomu, Nishioka, Yasuhiko
Publicado 2023

Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody

por Ichihara, Seiya, Ogino, Hirokazu, Yoneda, Hiroto, Haji, Keiko, Kagawa, Kozo, Murakami, Kojin, Mima, Masato, Aoi, Yu, Mitsuhashi, Atsushi, Tsukazaki, Yuki, Yabuki, Yohei, Ozaki, Ryohiko, Sato, Seidai, Nokihara, Hiroshi, Nishioka, Yasuhiko
Publicado 2022